79 results about "Drug regimen" patented technology

The invention relates to the technical field related to artificial intelligence, in particular to an intelligent medical diagnosis engine based on an AI large model, which comprises an auxiliary diagnosis module for collecting data such as an electronic medical record and a medical image of a patient and predicting an auxiliary result by using an integrated learning method; the drug recommendation module is used for analyzing drug recommendation data by using an AI large model and predicting potential curative effects and side effects of new drugs; and the operation simulation module is used for constructing an operation environment and a human body model in combination with a virtual reality technology. A large amount of medical data can be quickly processed and analyzed through auxiliary diagnosis, the diagnosis time is shortened, gene, physiological and pathological multi-omics data of a patient can be integrated by reducing unnecessary invasive examination and misdiagnosis and drug recommendation, a personalized drug treatment scheme is provided for the patient, and the patient experience is improved. Comprehensive and accurate diagnosis basis and treatment suggestions are provided for doctors; by accurately simulating a real operation scene including mechanical and optical characteristics, a more real training experience is provided for doctors and medical students.

The invention relates to an auxiliary diagnosis and treatment method, device and equipment and a storage medium, and the method comprises the steps: verifying the quality of medical data through an intelligent matching mechanism, and generating a supplementary signal containing standardized guidance for unqualified image data in real time; a cross-modal fusion technology is adopted to integrate the tongue image, the pulse image, the image and the inspection data, and a comprehensive feature vector of a unified dimension is constructed; outputting correlation mapping of the traditional Chinese medicine syndromes and the western medicine diseases based on the pathological reasoning model, and generating a drug treatment scheme and a non-drug treatment scheme through a treatment scheme reasoning model; and finally, dynamically optimizing the dialectical logic parameters and the treatment weight parameters according to user feedback. The method solves the problems of difficulty in multi-source medical data fusion, one-sided diagnosis basis and lack of curative effect feedback closed loop, significantly improves the accuracy and adaptability of personalized diagnosis and treatment, and provides standardized intelligent support for traditional Chinese and western medicine combined diagnosis and treatment.

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor(s) determining that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in an electronic health record (EHR) system communicatively coupled to the one or more processors. The processor obtains descriptive information relating to a patient. The processor selects a pharmacokinetic model. The processor applies the pharmacokinetic model and utilizes the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection. The processor generates rankings for the drug therapies and determines if the current drug regimen comprises a probability above a threshold. The processor generates a new order.

The invention relates to the technical field of Escherichia coli drug resistance analysis, in particular to an Escherichia coli antibiotic drug resistance detection method based on SERS and machine learning. The invention provides an Escherichia coli antibiotic resistance detection method based on SERS (Surface Enhanced Raman Scattering) and machine learning so as to overcome the defect that high-precision and rapid diagnosis cannot be realized in the prior art. The invention aims to realize rapid and high-precision identification of drug-resistant bacteria through a machine learning algorithm by utilizing a core-shell nanostructure SERS substrate of silver-coated gold nanoparticles and combining SERS spectrum differences of drug-resistant escherichia coli with different phenotypes. Through the method, the detection time can be remarkably shortened, the detection precision can be improved, an accurate drug treatment scheme is provided for clinic, and the method has a wide application prospect.

The invention provides a screening platform for chemotherapy combined anti-tumor natural products and application of the screening platform. PTC has tumor cells, interstitial cells, fibroblasts and immune cells from primary epithelium, is rich in cell components, and has advantages in the aspect of tumor microenvironment simulation. Meanwhile, PTC can reproduce tumor heterogeneity, the culture success rate and clinical consistency can reach 90% or above, and the detection period is within two weeks. And the detection result can be read through AI intelligent software, so that the accuracy can be further improved. The screening period can be shortened, the cost is reduced, and the accuracy is improved; according to the platform, high-throughput screening can be carried out in a short time, and the treatment effect of a chemotherapy drug combined anti-tumor natural product drug scheme can be predicted.

The invention relates to an application of an intervention SNRK-MTA1 signal channel axis in preparation of a non-small cell lung cancer targeted therapy drug. The nucleotide sequences of the mRNA of the SNRK gene and the mRNA of the MTA1 gene are respectively as shown in SEQ ID NO.1-2. The invention innovatively provides a strategy for treating the non-small cell lung cancer through double-target combined intervention. According to the strategy, SNRK gene expression is improved through exogenous gene overexpression plasmids, and meanwhile MTA1 gene expression is silenced through the siRNA technology. In a non-small cell lung cancer model, the strategy of combined application of the SNRK-OE plasmid and siMTA1 can specifically up-regulate the SNRK mRNA level and knock down the MTA1 mRNA level at the same time, and the combined strategy shows a better anti-tumor effect than single intervention, and can more effectively inhibit the growth and migration of tumor cells. Based on the discovery, the SNRK-MTA1 signal pathway axis can be developed into a novel therapeutic target for non-small cell lung cancer, and is used for designing a drug combination scheme or a composite targeted drug.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention relates to a recombinant complement protein and application thereof in preparation of anti-leukemia drugs, and belongs to the technical field of biological medicines. The invention discloses a method for treating acute leukemia by single drug, namely injecting recombinant C1QBP protein, which has a remarkable effect on treating acute leukemia, can be used for remarkably inhibiting proliferation of leukemia cells in marrow, spleen and peripheral blood of a hematopoietic system and also inhibiting infiltration of the leukemia cells in extramedullary organs (skin and the like), so that the whole-body tumor load is reduced, and the curative effect of treating acute leukemia is improved. The lifetime of leukemia mice is obviously prolonged. The recombinant C1QBP protein is combined with a clinical first-line chemotherapy regimen for use, has a synergistic effect, has a stronger effect of inhibiting leukemia cell proliferation compared with a single chemotherapy drug, can significantly prolong the lifetime of leukemia mice, and plays a role in reducing toxicity and enhancing efficacy. The invention proves that the complement C1Q binding protein has the effect of treating leukemia for the first time, provides a preparation method and a drug combination scheme, and has relatively high clinical transformation prospect and application value.

Introduced here are containers designed to promote compliance with regimens for administering the medications stored therein. These containers can facilitate the conveyance of information related to a regimen through the use of a non-written medium. A container may include one or more display elements configured to emit / reflect light to indicate when medication stored in the container should be administered. An example of a display element is a light-emitting diode (LED). Emittance / reflectance of the light by the display element(s) may be governed by a different clock signal than the clock signal used to determine whether doses of medication are due to be administered.

A method of supporting user adherence to a medication regimen includes storing received medication information associated with one or more medications using a patient wearable device and a coordinated care platform. The method also includes displaying identification and dosing information associated with the medications, generating a notification indicating that the identification information is being displayed, monitoring a response input indicating that the medications have been administered. For each of the one or more medications displayed, the method includes generating a medication status describing that either (i) the medication has been administered or (ii) the response has not been received. The method further includes generating a reminder notification when the medication status indicates that the response has not been received. The method may further include gathering behavioral data points associated with the user for submission to the coordinated care platform, which performs predictive analytics based on the data points.

The invention discloses a method and a system for identifying muscular weakness of a critical patient, and relates to the field of muscular weakness identification. Subjective clinical muscular strength grading of the patient and instrument detection data are integrated, a muscular weakness grade mapping model of multiple parts is established, and the diagnosis accuracy is greatly improved; through a host / guest part mapping model, namely in combination with subjective feeling and objective detection data of a patient, the medullary muscular weakness symptom prone to missed diagnosis in traditional examination can be identified; on the basis of a muscle weakness index data prediction mechanism, a muscle weakness crisis risk can be warned in advance; through a treatment-evaluation-adjustment closed-loop system, dynamic optimization of a medicine scheme is realized, the crisis occurrence rate can be greatly reduced, the dosage of an immunosuppressive agent is reduced, meanwhile, the treatment effect is maintained, and the system is suitable for patient groups managed for a long time; by establishing a mapping system of a part type set and an index grade set, quantitative unified evaluation of different types such as eye muscle type / whole body type and the like is realized, and subjective judgment errors are reduced.

The invention relates to the technical field of digital medical treatment and drug evaluation, in particular to an individualized drug curative effect and safety evaluation method and system based on digital twinborn and causal reinforcement learning. Individualized anti-fact prediction is realized through a patient digital twinning model, and potential curative effects and adverse event risks of different medication schemes can be evaluated on a single patient level. Meanwhile, an off-strategy causal reinforcement learning and dual-robust estimation method is adopted, the individualized value of a long-term sequential medication strategy is evaluated from observed real world data, and the preciseness of causal inference is improved; in addition, a curative effect-safety joint value function is constructed, curative effect benefits, safety risks and compliance cost are uniformly incorporated into the same decision framework, and multi-objective joint optimization is achieved; finally, an interpretability analysis report containing key features, value comparison and risk analysis is provided, the understanding and trust of clinicians on recommendation results are enhanced, and application and popularization in clinical practice are facilitated.

The invention discloses a cardiac valve postoperative management method based on cardiac function dynamic monitoring and analysis. A multi-modal dynamic monitoring system is innovatively constructed, a comprehensive sensor array and implantable monitoring equipment are fused, and multi-dimensional data such as electrocardio, blood pressure, myocardial strain and intracardiac pressure are comprehensively collected. A personalized digital heart model is built by means of a deep learning algorithm, a real-time risk assessment and early warning system is formed by combining big data and machine learning, and heart function changes and risks are accurately predicted. According to monitoring and analysis results, a drug treatment scheme is automatically and intelligently adjusted, and a personalized rehabilitation plan covering exercise, diet and psychological guidance is customized. By means of the method, precision and individuation of cardiac valve postoperative management are achieved, data integrity and accuracy are remarkably improved, the complication occurrence rate is effectively reduced, patient compliance is enhanced, and patient rehabilitation is powerfully promoted.

The invention relates to the technical field of drug therapy, in particular to a DRG paid drug therapy scheme analysis and evaluation method, device and system and a medium, and the method comprises the steps: obtaining the medical record information of an inpatient, the medical record information comprises the basic information, diagnosis information and treatment scheme information of the patient; matching a corresponding treatment cost standard in a DRG cost library based on the medical record information; matching a corresponding treatment drug combination in a drug database based on the treatment cost standard and the treatment scheme information; obtaining validity data of each drug in the therapeutic drug combination, and calculating the validity of the drug combination; and generating a drug treatment scheme recommendation sequence based on the drug combination validity, then obtaining historical drug use data of a patient, and correcting the recommendation sequence based on the historical drug use data to obtain a final recommendation scheme. Therefore, the effect of the DRG pharmaceutical composition on the patient can be comprehensively evaluated, and the effectiveness of treatment is improved.

The invention discloses a method for screening a medicine for treating recurrent glioma. The invention provides a method for screening a medicine for treating relapse brain glioma, which comprises the following steps: performing medicine treatment on in-vitro relapse brain glioma primary cells from a subject according to a candidate medication scheme, and detecting and comparing the activity of the relapse brain glioma primary cells under different medication schemes; and selecting a medicine with the strongest inhibition effect on the primary cells of the recurrent brain glioma as a treatment medicine for a corresponding subject. The invention proves that patients with brain glioma relapse can be screened by the method provided by the invention to obtain the most suitable drug treatment scheme.

In particular, this disclosure provides technologies, including I-66 formulations, compositions, and methods, for treating various cancers. This disclosure provides technologies, such as formulations, dosages, and drug regimens, for treating conditions, disorders, or diseases, in particular certain types of cancer. In some embodiments, this disclosure provides high-purity I-66 active pharmaceutical ingredients. In some embodiments, this disclosure provides I-66 pharmaceutical products. In some embodiments, this disclosure provides I-66 formulations, which are liquid compositions in which I-66 has sufficiently high solubility and stability for clinical application.

To provide dosing regimens of GLP-1 analogs for the treatment of fat, obese, overweight, nonalcoholic fatty liver disease (NAFLD), and / or nonalcoholic steatohepatitis (NASH).SOLUTION: Administering to the subject a first effective amount of one or more first active ingredients selected from the group consisting of GLP-1 and GLP-1 analogs; A dosing regimen is provided, comprising: a first effective amount administered continuously, or intermittently at an interval between two consecutive administrations of six hours or less; and one or more second active ingredients selected from the group consisting of a second effective amount of GLP-I and a GLP-1 analog, administered to said subject once daily, twice daily, three times daily, or four times daily.SELECTED DRAWING: None

A computer system, computer program product and method for determining a probability of attaining a PK-PD target associated with efficacy for a patient that includes a processor(s) determining that a trigger event related to a patient, wherein the patient record comprises an order for a current drug regimen, has occurred in an electronic health record (EHR) system communicatively coupled to the one or more processors. The processor obtains descriptive information relating to a patient. The processor selects a pharmacokinetic model. The processor applies the pharmacokinetic model and utilizes the information relating to the patient to determine, for each of the one or more drug therapies, a probability of attaining a PK-PD target associated with efficacy for the patient with the infection. The processor generates rankings for the drug therapies and determines if the current drug regimen comprises a probability above a threshold. The processor generates a new order.

The present application relates to the technical field of digital medicine and drug evaluation, and particularly relates to an individualized drug efficacy and safety evaluation method and system based on digital twinning and causal reinforcement learning. Through a patient digital twinning model, individualized counterfactual prediction is realized, which can evaluate the potential efficacy and adverse event risk of different drug regimens at the individual patient level. Meanwhile, off-policy causal reinforcement learning and double robust estimation methods are used to evaluate the individualized value of long-term sequential drug strategies from observational real-world data, improving the rigor of causal inference. In addition, a combined efficacy-safety value function is constructed, which unifies efficacy benefits, safety risks, and compliance costs into the same decision framework, enabling multi-objective joint optimization. Finally, an interpretable analysis report is provided, including key features, value comparisons, and risk analyses, which enhances clinicians' understanding and trust in the recommended results, facilitating the application in clinical practice.

Disclosed are a system, techniques and processes for monitoring and modifying a drug treatment regimen when a user partakes in a ketogenic diet. The disclosed system obtains ketone level measurements of a user and indicates a user's adherence to the ketogenic diet as well as modifying a user's total daily dosage of a drug based on the user's following the ketogenic diet.

A computer-implemented system for recording, tracking and reporting administration of one or more pharmaceutical treatment regimens, the system including one or more databases wherein details of one or more pharmaceutical treatment regimens are recorded, the databases accessible by processors associated with a first user device having access to the databases by a data communications network, the processors executing instructions that notify a first user, using the first user device, of details of a pharmaceutical treatment regimen associated with the first or second user, record details a pharmaceutical administration in accordance with treatment regimen entered by the first user using the first user device, and non-adherence to the treatment regimen by the first user, automatically notify another user, using a second user device wherein the another user has database access by the data communications network, of the non-adherence to treatment regimen by the first user.

Treatment of subjects experiencing cerebral ischemia is improved when the treatment employs a thrombolytic and an inhibitor against vascular endothelial growth factor receptor signal transduction (VEGF-RST) at a reduced, low dosage compared to that used to treat cancer patients. The treatment is also improved to permit point-of-care use by formulating protein drugs for long term stability at room temperature, providing doses appropriate for the method, and by combining the therapeutic agents with a point-of-care diagnostic for blood brain barrier integrity.

The invention provides a patient closed-loop management system and method based on drug-treatment scheme risk stratification, and relates to the technical field of medical monitoring, and the system comprises a monitoring data module which is used for obtaining medical environment data, body movement data, sleep data and core body health data through an intelligent medical terminal and a sensor; the user data module is used for acquiring historical medical data, basic data and historical monitoring data of the user; the sleep health module is used for determining a sleep health coefficient according to the user historical monitoring data, the user basic data, the historical medical data and the sleep data; the body health module is used for determining a body health coefficient according to the body movement data and the core body health data; the environment safety module is used for determining a medical environment safety coefficient according to the medical environment data; and the monitoring report module is used for determining a monitoring report. According to the invention, comprehensiveness and accuracy of patient closed-loop management can be improved.

The present application relates to the technical field of drug management, and discloses a kind of chronic kidney disease patient whole-course drug therapy wisdom management method and system, comprising: obtaining the electronic medical record of patient by the personal information of patient;Initial drug regimen is obtained based on electronic medical record and sent to medication decision unit, and final drug regimen is obtained based on medication decision unit, after confirming that drug code and drug quantity are consistent with drug code and drug quantity in final drug regimen, unit warehouse hash value is obtained using drug code, drug quantity and medication decision unit, drug reminder is generated according to final drug regimen, medication record is obtained using patient use port, and reconsultation reminder is obtained according to medication record, after sending the reconsultation reminder to patient use port and data storage unit, complete chronic kidney disease drug whole-process management.The present application can complete the drug management of chronic kidney disease patient and track medicine.

The invention provides a medical supervision platform. A patient personal information base and a pathology big database are established; the doctor inquires the patient according to the information of the patient information base and makes corresponding diagnosis; the supervision module compares and checks the diagnosis content of the proofreading doctor through big data; after checking, doctor diagnosis is input into a patient information base, and corresponding medical resources are allocated; the patient personal information base comprises basic information of patients, past medical history, medicine allergy history, examination results and uncomfortable symptoms, the pathology big database comprises disease names, disease indications, medicine principles and treatment modes, the platform can improve the accuracy and rationality of medical diagnosis, and by checking a medicine treatment scheme of a doctor, the medical diagnosis accuracy and rationality can be improved. And the treatment mode, the medicine type and the dosage are ensured to meet medical standards and patient requirements. The proofreading steps are helpful for reducing the risk of drug treatment and improving the treatment effect of patients.

A mesh network medication coordination system enables communication between intelligent injection devices, monitoring systems, patient devices, or healthcare provider devices to prevent adverse drug interactions in hospital settings. The system includes mesh network infrastructure supporting multiple networked devices, dosage measurement devices that directly measure or infer dosage administration including injection completion detection, medication volume measurement, administration timing data, or patient biometric responses, or a coordination module that coordinates medication administration timing across multiple devices. The system features drug interaction analysis capabilities, real-time monitoring of patient vital signs and medication effectiveness, alert generation for potential interactions and dosing conflicts, or data synchronization across all networked devices. This integrated approach optimizes dosing intervals, prevents conflicting medication schedules, synchronizes administration events, or maintains consistent medication administration data across the mesh network to enhance patient safety and treatment efficacy.

The invention provides a micro-fluidic chip and a tumor drug sensitivity detection system, and relates to the technical field of biological detection, the micro-fluidic chip comprises a substrate, a plurality of flow channels are formed between the substrate and a cover plate, one end of each flow channel is communicated with a drug feeding port and is provided with a first solenoid valve, and the other end of each flow channel is provided with a second solenoid valve; each three-dimensional culture cavity is sequentially arranged between the corresponding first electromagnetic valve and the corresponding second electromagnetic valve in the extending direction of the corresponding flow channel, and the position, flowing through the corresponding three-dimensional culture cavity, of each flow channel protrudes towards the cover plate and is in an arc shape; each three-dimensional culture cavity is provided with an input pipeline facing the first electromagnetic valve and an outlet facing the second electromagnetic valve, the input pipeline and the outlet are communicated with the flow channel, and the diameter of the input pipeline is smaller than that of the outlet. The method has the beneficial effects that a plurality of drug treatment schemes and combination strategies can be evaluated at the same time, high-throughput continuous multi-day culture of micro-tumors is realized, and the method can be applied to the fields of clinical individualized medication scheme formulation, new drug research and development, basic medical research and the like, so that precise treatment of lung cancer is promoted.

A method of supporting user adherence to a medication regimen includes storing received medication information associated with one or more medications using a patient wearable device and a coordinated care platform. The method also includes displaying identification and dosing information associated with the medications, generating a notification indicating that the identification information is being displayed, monitoring a response input indicating that the medications have been administered. For each of the one or more medications displayed, the method includes generating a medication status describing that either (i) the medication has been administered or (ii) the response has not been received. The method further includes generating a reminder notification when the medication status indicates that the response has not been received. The method may further include gathering behavioral data points associated with the user for submission to the coordinated care platform, which performs predictive analytics based on the data points.

A method for developing novel drug therapies utilizing properties of existing drug therapies, the method comprising the steps of: developing a novel therapeutic mathematical model of a target biological network and synthesizing a drug therapy based on the novel therapeutic mathematical model. The novel therapeutic mathematical model is capable of generating novel therapeutic time-course progressions, which include time-course progression features found in existing therapeutic time-course progressions of existing therapeutic mathematical models of the target biological network. The time-course progression features can be correlated with the outcomes of the target biological network. Each new therapeutic intervention constant can be used to synthesize a drug regimen, and these drug regimens collectively constitute the novel drug therapy.